Clinical trial
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
NCT07669051 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 1, 2026
- Completion date
- January 1, 2029
- Enrollment
- 36 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
nsclc (advanced non-small cell lung cancer)